Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 1/20 | 0.45 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.45 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SYNJ2 | O15056 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | BACE1 | P56817 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3564399 | 1.00 | LGALS8 (0.45) | LGALS8LGALS3LGALS4GAASYNJ2 | |
| SCHEMBL2735608 | 1.00 | LGALS8 (0.45) | LGALS8LGALS3LGALS4GAASYNJ2 | |
| SCHEMBL4379789 | 0.99 | LGALS8 (0.43) | LGALS8LGALS3LGALS4GAASYNJ2 | |
| SCHEMBL3572583 | 0.99 | LGALS8 (0.43) | LGALS8LGALS3LGALS4GAASYNJ2 | |
| SCHEMBL18386254 | 0.92 | LGALS3 (0.59) | LGALS8LGALS3LGALS4 | |
| SCHEMBL18386260 | 0.92 | LGALS3 (0.59) | LGALS8LGALS3LGALS4 | |
| SCHEMBL18386256 | 0.92 | LGALS3 (0.59) | LGALS8LGALS3LGALS4 | |
| SCHEMBL18386247 | 0.92 | LGALS3 (0.59) | LGALS8LGALS3LGALS4 | |
| SCHEMBL11949398 | 0.90 | GAA (0.45) | LGALS8LGALS3LGALS4GAAACHE | |
| SCHEMBL11949397 | 0.90 | GAA (0.45) | LGALS8LGALS3LGALS4GAAACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7846903-B2 | cubic liquid crystal formulation containing an amphiphilic compound such as 1-O-(5,9,13-trimethyltetradecyl)erythritol and a drug ( excluding a lysosomal enzyme) or cosmetic embedded in the cubic liquid crystal; time release agent | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2010-12-07 | — | — | US | disclosed |
| US-20080113923-A1 | Type II Cubic Liquid Crystal Composition | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE (JP) | 2008-05-15 | — | — | US | disclosed |
| EP-1813287-A1 | TYPE II CUBIC LIQUID CRYSTAL COMPOSITION | National Institute of Advanced Industrial Science and Technology (JP) | 2007-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113923-A1 | Type II Cubic Liquid Crystal Composition | AQP1, AQP3, SCO2 | LGALS8 1039/4885LGALS3 360/4885LGALS4 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.